CCL2 (MCP-1): Complete Research Profile — CCR2 Receptor Axes, NF-κB and AP-1 Transcriptional Control, Monocyte/Macrophage Recruitment, Tumor Microenvironment Biology, and Inflammatory Disease Research Applications (2026)

# CCL2 (MCP-1): Complete Research Profile — CCR2 Receptor Axes, NF-κB and AP-1 Transcriptional Control, Monocyte/Macrophage Recruitment, Tumor Microenvironment Biology, and Inflammatory Disease Research Applications (2026)

For Research Use Only (RUO) — Not for human or veterinary use

---

Introduction: CCL2 as the Defining Monocyte Chemoattractant

CCL2, originally designated Monocyte Chemoattractant Protein-1 (MCP-1), is a CC-chemokine subfamily member and the founding member of the MCP family (CCL2, CCL7, CCL8, CCL12, CCL13). Identified and cloned in 1989–1990 by multiple groups studying monocyte recruitment to inflamed tissues, CCL2 rapidly emerged as the primary chemotactic signal for classical CCR2+ monocytes, dendritic cell precursors, memory T cells, NK cells, and basophils. It is produced by an extraordinarily broad array of cell types including monocytes, macrophages, endothelial cells, fibroblasts, smooth muscle cells, epithelial cells, astrocytes, microglia, and tumor cells, making it one of the most broadly expressed chemokines in inflammatory biology.

CCL2's biological significance spans virtually all major inflammatory research domains. In atherosclerosis, CCL2-driven monocyte recruitment to the arterial wall is the rate-limiting step in foam cell formation and plaque initiation. In cancer, tumor-derived CCL2 is a dominant mechanism for recruitment of immunosuppressive tumor-associated macrophages (TAMs) from CCR2+ circulating monocytes. In neuroinflammation, CCL2 from reactive astrocytes and microglia drives monocyte infiltration into the CNS parenchyma — pathologically in neurodegeneration and beneficially in recovery from acute injury. And in metabolic disease, adipose tissue CCL2 drives macrophage infiltration and chronic low-grade inflammation critical for insulin resistance research models.

For research investigators, CCL2 is valuable across five converging programs: (1) monocyte/macrophage biology and recruitment assay design; (2) atherosclerosis and cardiovascular inflammatory research; (3) tumor microenvironment and TAM biology; (4) neuroinflammation models (stroke, MS, neurodegeneration); and (5) metabolic inflammation (obesity, type 2 diabetes adipose biology). This profile provides the mechanistic and practical research foundation across these areas.

---

Molecular Architecture

Protein Structure

Mature human CCL2 is a 76-amino-acid protein (8.9 kDa monomer) generated by cleavage of a 23-residue signal peptide from the 99-amino-acid precursor. Like all CC chemokines, CCL2 contains two adjacent N-terminal cysteines (no intervening residue) that form the CC motif — in CCL2 these are Cys11 and Cys12, forming disulfide bonds with Cys36 and Cys52 respectively, stabilizing the canonical chemokine fold.

CCL2 crystallizes as a dimer with the interface formed through the first β-strand and the N-loop. The physiologically relevant form for receptor activation is the monomer — CCL2 dimerization is primarily relevant for heparan sulfate proteoglycan (HSPG) binding and gradient formation at vascular surfaces. At concentrations relevant for receptor activation in solution-based assays (<100 nM), the monomer predominates.

N-terminal processing: Like CXCL10, CCL2 undergoes significant N-terminal processing by CD26/DPP4 and by matrix metalloproteinases (particularly MMP-2 and MMP-9). DPP4 cleavage removes Pro-Gly from the N-terminus to generate CCL2(3–76), which has substantially reduced CCR2 agonist activity. This processing has implications for assay design in serum-containing or MMP-rich environments.

The MCP Family Context

CCL2 shares ~55–70% sequence identity with CCL7 (MCP-3), CCL8 (MCP-2), and CCL13 (MCP-4). All MCP family members bind CCR2, but with different selectivity profiles:

• •CCL2: Primary CCR2 agonist; also binds CCR4 (low affinity)
• •CCL7 (MCP-3): Broader receptor profile — CCR1, CCR2, CCR3; important to consider when using pan-MCP blocking strategies
• •CCL8 (MCP-2): Binds CCR2, CCR3, CCR5; less selective than CCL2
• •CCL13 (MCP-4): CCR2, CCR3; important in eosinophil recruitment contexts

In blocking experiments using anti-CCL2 antibodies, investigators should confirm whether residual monocyte recruitment is CCL7/CCL8-dependent, particularly in chronic inflammatory models where multiple MCPs may be elevated.

---

CCR2 Receptor Biology

CCR2 Isoforms

CCR2 exists as two splice variants that differ in their C-terminal cytoplasmic tails:

• •CCR2A: 374 amino acids; predominant in smooth muscle cells and monocytes in some contexts
• •CCR2B: 360 amino acids; predominant in monocytes and macrophages; most extensively studied form in inflammatory research

Both isoforms bind CCL2 with similar affinity (Kd ~1–5 nM) but differ in desensitization kinetics and internalization rates, which can affect sustained signaling in chronic inflammatory conditions.

CCR2 Expression and the Classical Monocyte Subset

CCR2 is the defining surface marker of classical inflammatory monocytes:

• •Human: CD14++ CD16− CCR2hi monocytes (70–85% of blood monocytes) are CCR2-dependent for tissue egress from bone marrow and migration to inflammatory sites
• •Mouse: Ly6Chi CCR2+ monocytes are the inflammatory "patrolling" (actually tissue-infiltrating) subset; distinct from Ly6Clo CX3CR1hi non-classical monocytes (which are CCR2-low)

CCR2 deficiency (CCR2 KO mouse) produces marked monocytosis (monocytes accumulate in bone marrow, unable to egress) and protection from monocyte-dependent inflammatory pathology — a seminal genetic tool that defined CCR2's role in multiple disease models.

Beyond monocytes, CCR2 is expressed on:

• •Plasmacytoid dendritic cell precursors (pre-pDC)
• •Memory CD4⁺ and CD8⁺ T cells (CCR2+ memory T cells home to peripheral inflamed tissues)
• •Basophils
• •NK cell subsets
• •Bone marrow-derived dendritic cell precursors

CCR2 Signaling

CCL2:CCR2B engagement activates:

Gαi pathway:

• •Adenylyl cyclase inhibition → reduced cAMP (counteracts PKA-mediated cytoskeletal rigidity)
• •Gβγ → PLCβ2/3 → IP3 → Ca²⁺ mobilization (peak within 20–30 seconds; detectable by Fura-2 or Fluo-4)
• •Gβγ → PI3K-γ → PIP3 → Akt → pro-survival and cytoskeletal signals
• •Rac1 and RhoA GTPase activation → lamellipodia (leading edge) and actomyosin contractility (trailing edge retraction) for directed migration

ERK1/2 and p38 MAPK:

Activated via Ras-dependent and β-arrestin-dependent pathways. ERK1/2 in CCR2+ monocytes contributes to:

• •Matrix metalloproteinase (MMP-9, MMP-2) upregulation for extracellular matrix remodeling during diapedesis
• •Inflammatory cytokine production (TNF-α, IL-1β) in macrophages after CCL2-driven tissue entry

β-Arrestin pathway:

CCR2B undergoes rapid β-arrestin1/2 recruitment and GRK2/3-mediated phosphorylation → receptor internalization via clathrin-coated vesicles. β-Arrestin:CCR2 complexes activate ERK1/2 independently of Gαi. Biased CCL2 variants that preferentially recruit β-arrestin vs. Gαi are used in research to dissect the respective pathway contributions to chemotaxis vs. cytokine production.

---

Transcriptional Regulation of CCL2

NF-κB as the Primary Driver

The CCL2 promoter (−1400 to TSS) contains multiple NF-κB binding sites, with the most critical at −2.7 kb (distal) and −95 bp (proximal). NF-κB p65/p50 binding is essential for:

• •LPS-induced CCL2 in macrophages (via TLR4 → TRIF/MyD88 → IKK → NF-κB)
• •TNF-α and IL-1β-driven CCL2 (canonical NF-κB pathway)
• •ROS-mediated CCL2 (oxidized LDL → NF-κB in endothelial cells)

NF-κB is necessary but not sufficient for maximal CCL2 induction — transcriptional co-factors AP-1 and SP-1 provide synergistic activation.

AP-1 and the JNK Pathway

The CCL2 proximal promoter contains an AP-1 site at −100 bp (c-Jun/c-Fos binding element). JNK → c-Jun phosphorylation → AP-1 → CCL2 represents a parallel transcriptional axis important for:

• •Growth factor-induced CCL2 (PDGF, EGF via Ras-JNK)
• •Oxidative stress-induced CCL2 (ROS → ASK1 → MKK4/7 → JNK)
• •Hypoxia-induced CCL2 (HIF-1α synergizes with AP-1)

JNK inhibitor SP600125 (10–20 µM) selectively blocks AP-1-dependent CCL2 while partially sparing NF-κB-dependent CCL2 — a useful tool for pathway dissection.

SP-1, HIF-1α, and Other Regulatory Inputs

• •SP-1: Three SP-1 sites in CCL2 proximal promoter; constitutive basal activity; important for tumor cell CCL2 expression
• •HIF-1α: HRE at −600 bp; hypoxia (1% O₂) induces CCL2 2–5-fold in endothelial cells and tumor cells; relevant for hypoxic tumor microenvironment research
• •PPARγ: Negative regulator; PPARγ activation (rosiglitazone, 15d-PGJ2) suppresses NF-κB-driven CCL2 — mechanistic basis for anti-inflammatory effects of PPARγ agonists on monocyte recruitment

---

Heparan Sulfate Proteoglycan Interactions

CCL2 binds heparan sulfate through its C-terminal α-helix basic residues (Arg18, Lys19, Arg24 — the "40s loop" region). HSPG binding:

• •Immobilizes CCL2 on endothelial surfaces and extracellular matrix, forming the haptotactic gradient that guides CCR2+ monocyte rolling → arrest → diapedesis
• •The CCL2 dimer (anti-parallel orientation confirmed by NMR) is the preferred HSPG-binding form; monomers bind HS with ~10-fold lower affinity
• •Mutations disrupting CCL2:HSPG binding (P8A, R18A) generate CCL2 variants that circulate without forming surface gradients — used in research to prove that gradient formation (not soluble CCL2) is required for in vivo monocyte recruitment

The HSPG-dependent gradient mechanism is critical context for interpreting in vitro vs. in vivo CCL2 biology: transwell assays measure soluble CCL2 gradient responses, but physiological monocyte recruitment is primarily haptotactic and HSPG-dependent.

---

CCL2 in Tumor Microenvironment Research

TAM Recruitment via CCL2/CCR2

Tumor-associated macrophages (TAMs) are among the most abundant immune cells in solid tumors and correlate with poor prognosis across multiple cancer types. CCL2 produced by tumor cells, cancer-associated fibroblasts (CAFs), and endothelial cells is the primary driver of CCR2+ monocyte recruitment to tumors, where they differentiate into immunosuppressive TAMs.

TAM-promoting CCL2 production triggers in tumors:

• •Tumor hypoxia → HIF-1α → CCL2 from tumor cells and endothelial cells
• •Tumor-derived CSF-1/M-CSF synergizes with CCL2 for TAM differentiation
• •TGF-β from the ECM activates NF-κB-independent CCL2 in CAFs
• •Damaged DNA or oncogene activation (KRAS) constitutively activates NF-κB → CCL2

TAM biology downstream of CCL2 recruitment:

Once recruited, CCR2+ monocytes differentiate into TAMs under the influence of tumor-derived IL-4, IL-13, CSF-1, and IL-10. TAMs suppress cytotoxic immunity via:

• •Arginase-1 expression (arginine depletion → T cell impairment)
• •PD-L1 upregulation (immune checkpoint)
• •IL-10 and TGF-β secretion
• •VEGF production (angiogenesis support)

In vitro TAM research models:

1. CCL2-driven monocyte migration to tumor conditioned medium:

- Collect tumor cell line conditioned medium (CM) from 48h cultures (MCF-7, MDA-MB-231, HCT116)

- Measure CCL2 in CM by ELISA (R&D DuoSet DY279: range 31.2–2000 pg/mL)

- Use CM as chemoattractant in 8 µm transwell assay with freshly isolated CD14+ monocytes

- Add anti-CCL2 neutralizing Ab (10 µg/mL, R&D MAB279) to upper chamber; quantify CCL2-dependent vs. CCL2-independent migration components

2. Monocyte-to-TAM differentiation:

- CD14+ monocytes + tumor CM (50% v/v) for 5–7 days

- Characterize TAM phenotype: CD163+, CD206+, HLA-DRlo, CCR2 downregulation (TAMs downregulate CCR2 upon tissue entry), CD14+ maintained

- Measure IL-10, TGF-β secretion (ELISA) and arginase activity

CCL2 and the "Metastatic Niche"

CCL2 has been identified as a key mediator of pre-metastatic niche formation and metastatic colonization:

• •Primary tumors secrete CCL2 into systemic circulation; CCL2 recruits inflammatory monocytes to pre-metastatic sites (particularly lung and bone marrow niches)
• •CCR2+ monocytes in pre-metastatic niches promote tumor cell extravasation and survival through perlecan and fibronectin matrix remodeling
• •CCL2 drives TAM-mediated angiogenesis at metastatic sites, creating a "metastatic vascular niche"

Research models for pre-metastatic niche: injection of conditioned medium or CCL2 protein into naive mice → flow cytometry quantification of Ly6Chi (murine) monocyte accumulation in lung and bone marrow at 24–72h.

---

CCL2 in Atherosclerosis Research

The atherosclerosis research application of CCL2 is one of the best-validated chemokine-disease connections in biomedical science:

• •CCL2 KO × ApoE KO mice: Reduced early atherosclerotic lesion formation and macrophage accumulation in the aortic root vs. ApoE KO alone
• •CCR2 KO × ApoE KO mice: Similar protection, confirming CCL2/CCR2 axis drives lesion initiation
• •Mechanism: Oxidized LDL (oxLDL) in the arterial intima → endothelial cell and smooth muscle cell NF-κB/AP-1 → CCL2 production → CCR2+ monocyte recruitment → intimal macrophage → foam cell

In vitro atherosclerosis-relevant CCL2 assays:

• •Human coronary artery endothelial cells (HCAEC) + oxLDL (50 µg/mL, 24h): Measure CCL2 in supernatant by ELISA; expected: 5–50-fold induction vs. untreated
• •HUVEC + TNF-α (10 ng/mL, 6h): Robust CCL2 induction (typically 500–5000 pg/mL); validates TNF-α-NF-κB-CCL2 pathway in endothelial research
• •Monocyte rolling/adhesion under flow: CCL2-coated microfluidic channels at 1 dyn/cm² shear stress; anti-CCR2 (clone R&D MAB150) reduces rolling velocity, confirming CCR2-dependent arrest

---

CCL2 in Neuroinflammation Research

Astrocyte and Microglial CCL2

In the CNS, CCL2 is produced by reactive astrocytes, activated microglia, and neurons in response to injury, infection, or neurodegenerative stimuli:

• •Primary murine astrocytes: LPS (1 µg/mL) or IL-1β (10 ng/mL) + TNF-α (10 ng/mL) → CCL2 induction (ELISA: 500–5000 pg/mL in 24h supernatant)
• •Hippocampal/cortical neuron cultures: Kainic acid excitotoxicity or Aβ oligomer exposure → CCL2 from neurons; drives microglial activation and recruitment
• •Human iPSC-derived astrocytes: Responsive to IL-1α + TNF-α + C1q "reactive astrocyte" cocktail; CCL2 is among the highest-induced chemokines in this activation paradigm

CNS-derived CCL2 drives infiltration of CCR2+ peripheral monocytes into the brain parenchyma in models of:

• •Stroke (ischemia/reperfusion): Early CCL2 from ischemic neurons and astrocytes; CCR2 KO mice have reduced monocyte infiltration and altered infarct outcomes
• •Multiple sclerosis (EAE): CCL2 from inflamed spinal cord endothelium drives CCR2+ monocyte transmigration across blood-brain barrier; CCL2 is elevated in CSF of active MS

---

In Vitro Research Protocols

CCL2 Induction Assay

Standard multi-stimulus CCL2 production comparison:

1. Seed cells (THP-1 monocytes differentiated to macrophages with PMA; primary human monocyte-derived macrophages; HUVEC; primary fibroblasts) at standard density

2. Stimulate with panel: LPS (100 ng/mL), TNF-α (10 ng/mL), IL-1β (10 ng/mL), oxLDL (50 µg/mL), hypoxia (1% O₂, 16h), vehicle control

3. Collect supernatants at 6h, 12h, 24h

4. CCL2 ELISA (R&D DuoSet DY279): measure pg/mL; confirm mRNA induction by RT-qPCR at 2h, 6h time points

5. Pathway inhibitors (30 min pre-treatment): BMS-345541 (IKK, 5 µM), SP600125 (JNK, 20 µM), SB203580 (p38, 10 µM) to attribute CCL2 to specific transcription programs

CCR2-Dependent Monocyte Chemotaxis

1. Isolate CD14+ monocytes from PBMC (negative selection, Miltenyi or STEMCELL)

2. Confirm CCR2 expression by flow cytometry (anti-CCR2-PE, clone K036C2, BioLegend #357204): expected >70% CCR2+

3. Resuspend in serum-free RPMI; load 5×10⁵ in 100 µL into 8 µm transwell upper chamber

4. Lower chamber: CCL2 (0.1–1000 ng/mL concentration-response; optimal ~10–50 ng/mL for maximal CI)

5. Migrate 90 minutes (37°C, 5% CO₂)

6. Count by hemocytometer or CytoFluor (calcein-labeled)

7. Specificity control: CCR2 antagonist RS504393 (10 µM) or BMS CCR2 22 (1 µM) in upper chamber; should reduce CI to ~1.0

8. Express as Chemotaxis Index (CI) = migrated in CCL2 / migrated in medium

Typical CI for primary human monocytes at 10 ng/mL CCL2: 3–8-fold.

---

Pharmacological Research Tools

---

Key Research Citations

1. Yoshimura T, Yuhki N, Moore SK, et al. Human monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE. FEBS Lett. 1989;244(2):487–493. PMID: 2784222. https://pubmed.ncbi.nlm.nih.gov/2784222/

2. Boring L, Gosling J, Cleary M, Charo IF. Decreased lesion formation in CCR2−/− mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998;394(6696):894–897. PMID: 9732871. https://pubmed.ncbi.nlm.nih.gov/9732871/

3. Gu L, Okada Y, Clinton SK, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998;2(2):275–281. PMID: 9734366. https://pubmed.ncbi.nlm.nih.gov/9734366/

4. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549–555. PMID: 12401408. https://pubmed.ncbi.nlm.nih.gov/12401408/

5. Qian BZ, Li J, Zhang H, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature. 2011;475(7355):222–225. PMID: 21654748. https://pubmed.ncbi.nlm.nih.gov/21654748/

6. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29(6):313–326. PMID: 19441883. https://pubmed.ncbi.nlm.nih.gov/19441883/

---

All information is provided for research purposes only. CCL2 and related materials are research reagents for in vitro laboratory investigation. Not for use in humans or animals. Investigators should consult institutional biosafety guidelines when working with recombinant chemokines.